Navigation Links
The Leukemia & Lymphoma Society Available to Comment on FDA Approval of Seattle Genetics' Adcetris, First New Treatment for Hodgkin Lymphoma Since 1977
Date:8/19/2011

WHITE PLAINS, N.Y., Aug. 19, 2011 /PRNewswire/ -- Today the Food and Drug Administration (FDA) approved Seattle Genetics' Adcetris to treat two types of rare blood cancers – Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL).

(Logo: http://photos.prnewswire.com/prnh/20110215/NY48642LOGO)

The drug is approved for Hodgkin lymphoma patients after failure of a stem cell transplant or two chemotherapy treatments and for ALCL patients after failure of at least one multi-agent chemotherapy treatment.

"This is a great advance for patients battling both of these diseases," said Hildy Dillon, Senior Vice President of Patient Services for The Leukemia & Lymphoma Society. "These are both considered very curable diseases but there is a population of patients from both diseases for whom treatment has not been effective."

Hodgkin lymphoma has an 86 percent survival and ALCL has an 80 percent cure rate.

"But for those people who don't respond well these can be very difficult cancers to cure. This advance gives new hope to that group of patients," Dillon said.

Dillon added that Seattle Genetics should be commended for investing in a therapy for a very small subgroup of patients who don't respond to standard therapy and for whom there were very limited options until now.

There are nearly 9,000 new cases of Hodgkin lymphoma diagnosed each year and 3,000 new cases of ALCL, and both diseases primarily impact children in their late teens and young adults.  Adcetris is a targeted therapy linking a tumor-targeting antibody to a chemotherapy drug with the goal of limiting side effects.

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society® (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and support services.

Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada. To learn more, visit www.LLS.org or contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET. www.LLS.org.

For LLS Contact:
Andrea Greif
Work: 914-821-8958
Cell: 914-772-3027
andrea.greif@lls.org


'/>"/>
SOURCE The Leukemia & Lymphoma Society
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Perdue Kidd & Vickery Files Lawsuit Against Abbott Laboratories for Inadequate Leukemia and Cancer Warning
2. Recent Study Shows Leukothera™ Combined with Other Agents Has Enhanced Anti-Leukemia Effects
3. Financial Assistance Now Available for People with Acute Lymphoblastic Leukemia
4. Omeros Unlocks Orphan GPCRs Linked to Leukemia and Sleep Disorders
5. Wake Forest Baptist Medical Center and Cornerstone Pharmaceuticals Present Interim Data From Phase I Trial of CPI-613 in Acute Myeloid Leukemia
6. Medco Partners With MolecularMD on Personalized Medicine Program for Chronic Myeloid Leukemia
7. Reportlinker Adds Triple Analysis: Leukemia, Lymphoma and Peptides
8. Reportlinker Adds Triple Analysis: Breast Cancer, Leukemia and Cancer Vaccines
9. Reportlinker Adds Triple Analysis: Leukemia, Lymphoma and Pancreatic Cancer
10. Reportlinker Adds Triple Analysis: Leukemia, Prostate Cancer and Apoptosis
11. Reportlinker Adds Triple Analysis: Colorectal Cancer, Leukemia and Apoptosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... -- IRIDEX Corporation (NASDAQ: IRIX ) today announced ... stock, $0.01 par value (the "Offering" with such shares being ... terms of the Offering will depend on market and other ... no assurance as to whether or when the Offering may ... proceeds it will receive from this offering for working capital ...
(Date:12/8/2016)... 8, 2016 Global Interventional Radiology Market: ... global interventional radiology market analyzes the current and ... an elaborate executive summary, including a market snapshot ... sub-segments. The research is a combination of ... bulk of our research efforts along with information ...
(Date:12/8/2016)... -- Eli Lilly and Company (NYSE: LLY ) ... trial at the 9 th Clinical Trials on ... not meet the primary endpoint in the EXPEDITION3 clinical ... mild dementia due to Alzheimer,s disease (AD), and Lilly ... treatment of mild dementia due to AD. ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... After enjoying ... opened registration today for its 33rd Annual Issues & Research Conference, March ... The theme of the conference is “Persistent Challenges and New Opportunities: Using Research ...
(Date:12/8/2016)... ... December 08, 2016 , ... CURE Media Group, the nation’s ... groups, has aligned with Upstage Lung Cancer in efforts to combat lung cancer, announced ... J. Hennessy, Jr said, “CURE Media Group is honored to team up with Upstage ...
(Date:12/8/2016)... ... December 08, 2016 , ... Launching of ... Unified Instance Manager architecture, meeting the needs of multichannel growth and doubling ... unattended auto-dialing system without agents, Presence Robodialer, provides greater operational capacity, administrative ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... surgery as possible. With this in mind, SIGVARIS has created a new line ... clot) during bed rest and provide the benefits of graduated compression when transitioning ...
(Date:12/8/2016)... ... 08, 2016 , ... The Dan Carlisle Agency, an Alabama-owned ... is announcing the launch of a charity drive to raise support and awareness ... and children in Birmingham has grown steadily since the 1980’s, and the Pathways ...
Breaking Medicine News(10 mins):